StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen tEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q2 2026
486
Period ended Jun 30, 2026
Change on a year earlier
+42.1%
342 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
13
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026486+42.1%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026343+20.4%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025474+60.1%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025377+40.1%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025342+46.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025285+64.7%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024296+67.2%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024269+67.1%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024234+75.9%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024173+80.2%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023177+124.1%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023161+192.7%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023133+358.6%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 202396+1,271.4%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 202279–Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202255–Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗

Breakdown

What makes up tezspire (tezepelumab-ekko — severe asthma) — worldwide product sales ($m)

Cite this data

StockData. (2026). Amgen TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M) ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_tezspire_ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.